10-Q: Neurocrine Biosciences Reports Strong Q3, Advances Pipeline

Neurocrine Biosciences reports significant revenue growth driven by INGREZZA and CRENESSITY sales, alongside multiple pipeline advancements, despite increased operating expenses and a Phase 3 clinical trial setback.

Summary

• Total revenues for the three months ended September 30, 2025, increased to $794.9 million from $622.1 million in the prior year period.
• Net product sales for INGREZZA grew to $686.6 million in Q3 2025, up from $612.9 million in Q3 2024, driven by strong patient demand.
• CRENESITY, launched in December 2024, contributed $98.1 million in net product sales for Q3 2025 and $165.8 million for the first nine months of 2025.
• Net income for Q3 2025 rose to $209.5 million ($2.04 diluted EPS) from $129.8 million ($1.24 diluted EPS) in Q3 2024.
• For the first nine months of 2025, total revenues reached $2,055.0 million, compared to $1,727.6 million in the same period last year.
• Nine-month net income increased to $324.9 million ($3.19 diluted EPS) from $238.2 million ($2.29 diluted EPS) in the prior year, benefiting from the absence of convertible senior notes charges.
• Operating expenses increased significantly, with R&D at $250.0 million for Q3 2025 (vs. $195.0 million in Q3 2024) and SG&A at $291.6 million (vs. $234.3 million in Q3 2024), reflecting investments in commercialization and pipeline.
• Initiated two Phase 3 clinical studies for direclidine in schizophrenia and a Phase 3 study for osavampator in Major Depressive Disorder (MDD).
• A Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint.
• INGREZZA qualified for the small biotech exception under the Medicare Drug Price Negotiation Program, exempting it from selection until 2027 for initial price applicability in 2029.
• Expanded formulary access for INGREZZA to approximately 70% of TD and Huntington's disease Medicare beneficiaries.
• The Board authorized a new $500.0 million share repurchase program in February 2025, with $167.7 million repurchased and $332.3 million remaining as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and net income growth driven by key product sales. Pipeline advancements are robust, with multiple programs entering late-stage development and positive clinical data. Strategic market positioning for INGREZZA is favorable. While operating expenses increased and one Phase 3 study failed, these are largely offset by overall growth and strategic investments. The company is actively managing legal and regulatory challenges, which are inherent in the industry.

Positives

• Strong growth in net product sales for INGREZZA, driven by robust patient demand.
• Successful launch and initial sales contribution from CRENESITY, a first-in-class FDA-approved treatment for CAH.
• Significant increase in net income and diluted EPS for both the three and nine-month periods.
• Advancement of multiple pipeline candidates into later-stage clinical trials, including two Phase 3 studies for direclidine in schizophrenia and one Phase 3 study for osavampator in MDD.
• Positive top-line data from the Phase 4 KINECT-PRO study for INGREZZA, demonstrating sustained symptomatic remission and improved patient-reported outcomes in tardive dyskinesia.
• Positive data from the Phase 2 SAVITRI study for osavampator, showing statistically significant and clinically meaningful improvement in depression severity.
• INGREZZA's qualification for the small biotech exception under the Medicare Drug Price Negotiation Program provides protection from price negotiation until 2029.
• Expanded formulary access for INGREZZA significantly improves coverage for Medicare beneficiaries.
• Authorization of a new $500.0 million share repurchase program demonstrates commitment to returning capital to shareholders.

Negatives

• Operating income for the nine months ended September 30, 2025, decreased to $408.2 million from $428.5 million in the prior year, primarily due to increased operating expenses.
• Increased R&D expenses reflect higher investment in late-stage programs and gene therapy, but also include a failed Phase 3 study for valbenazine in schizophrenia.
• Increased selling, general, and administrative expenses due to continued investment in commercial organization expansion and CRENESITY launch activities.
• Lower net price for INGREZZA due to new market access investments, partially offsetting demand-driven sales growth.
• The Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint, indicating a setback for this specific indication.

Risks

• Inability to successfully commercialize INGREZZA or CRENESITY, or achieve anticipated market acceptance and physician/patient adoption.
• Intense competition from existing and emerging products, including generic equivalents, which could reduce demand for products.
• Government and third-party payors imposing sales and pharmaceutical pricing controls, limiting coverage/reimbursement, or making adverse policy decisions (e.g., IRA, OBBBA, state PDABs, drug importation).
• Technological uncertainty in product candidate development, leading to potential ineffectiveness, harmful side effects, or failure to receive regulatory approvals.
• Clinical trial delays or failures to demonstrate safety and efficacy, potentially preventing or significantly delaying regulatory approval.
• Difficulties in managing organizational growth, including recruiting and retaining qualified personnel, and integrating new systems like the ERP.
• Challenges in transforming R&D strategies to include biologics development, requiring substantial investment and new expertise.
• Potential side effects or adverse events associated with approved products or product candidates, impacting demand or regulatory approval.
• Dependence on a limited number of third-party suppliers for manufacturing, risking supply disruptions or quality issues.
• Reliance on current and future collaborators for development and commercialization, which may lead to lack of control or disputes.
• Absence of internal manufacturing capabilities, increasing reliance on contract manufacturers and exposure to their compliance and performance risks.
• Inability to protect intellectual property, including challenges from competitors, ANDA filings for generic versions, and potential impacts from generative AI technologies.
• Customer concentration, with four customers representing over 90% of total gross product sales, posing a risk if a significant customer is lost.
• Need for additional capital in the future, with no assurance of availability on reasonable terms, potentially leading to dilution or restrictive debt covenants.
• Volatility of common stock price due to various factors, including clinical trial results, regulatory developments, and analyst expectations.
• Share repurchase programs may not enhance long-term stockholder value or prove to be the best use of cash.
• Compliance with changing laws and standards related to corporate governance, workforce initiatives, and public disclosure, leading to increased expenses and potential litigation.
• Potential liability from promoting off-label uses of products, leading to significant civil or criminal sanctions.
• Compromise of information technology systems, third-party systems, or data, leading to operational interruptions, data breaches, reputational harm, and regulatory actions.
• Unfavorable geopolitical and macroeconomic developments, including tariffs, trade barriers, and military conflicts, affecting supply chains and business operations.
• Failure to obtain or maintain orphan drug designation or other regulatory exclusivity for product candidates.
• Infringement of third-party patents or proprietary rights, leading to litigation, licensing costs, or inability to commercialize products.
• Exposure to disputes, claims, and lawsuits, which can be costly, time-consuming, and impact financial results.
• Employee or independent contractor misconduct, including non-compliance with regulatory standards and fraud and abuse laws.
• Potential product liability exposure exceeding insurance coverage.
• Liability for contamination or injuries from hazardous materials used in research activities.
• Stringent and changing obligations related to data privacy and information security, including GDPR, CCPA, cross-border transfers, and generative AI, leading to compliance costs and potential penalties.

Future Outlook

The company anticipates continued commercial success for INGREZZA and CRENESITY, supported by ongoing investments in its commercial organization and an expanded pre-clinical and clinical portfolio. Management believes existing capital resources, anticipated product sales, and investment income will be sufficient to meet funding requirements for at least the next 12 months. Future capital requirements will depend on the commercial success of products, scientific progress in R&D, costs of regulatory approvals, patent enforcement, and potential strategic alliances. The company expects to increase expenses for the foreseeable future as it funds operations and capital expenditures, aiming to sustain growth and profitability.

Management Comments

• "We believe that our existing capital resources, funds generated by anticipated INGREZZA and CRENESSITY net product sales, and investment income will be sufficient to satisfy our current and projected funding requirements for at least the next 12 months."
• "Key elements of our commercial strategy include maximizing the opportunities in INGREZZA and CRENESSITY through consistent and effective commercial execution, continued development of valbenazine as the best-in-class treatment for new patient populations, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease."

Industry Context

The pharmaceutical industry is experiencing significant regulatory changes, including the implementation of the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), which impact drug pricing and tax deductibility of R&D expenses. Increased government scrutiny on drug pricing, direct-to-consumer advertising, and data privacy (e.g., GDPR, CCPA) is creating a complex operating environment. Geopolitical tensions and trade policies, including potential tariffs on pharmaceutical imports, also pose risks to global supply chains and costs. The industry is seeing a shift towards biologics and gene therapies, requiring substantial investment and specialized expertise. Neurocrine Biosciences is actively navigating these trends by expanding its pipeline into biologics, managing regulatory compliance, and strategically positioning its key products like INGREZZA against competitive pressures from other VMAT2 inhibitors (e.g., Teva's AUSTEDO) and generic threats.

Comparison to Industry Standards

• INGREZZA competes with Teva Pharmaceuticals Industries' AUSTEDO (deutetrabenazine) for tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR, a once-daily dosing, was introduced in February 2023. The Medicare drug negotiation program selected AUSTEDO and AUSTEDO XR for negotiation in 2025 (for 2027 applicability), which may increase competitive pressure on INGREZZA.
• CRENESITY competes with high-dose corticosteroid monotherapy, the current standard of care for CAH. The market includes over two dozen companies manufacturing steroid-based products, and several other companies have programs in clinical development targeting CAH.
• The company's investigational treatments for schizophrenia and depression will compete with numerous existing anti-psychotic and anti-depressant medications and several development-stage programs from other companies.
• Neurocrine's expansion into biologics, including gene therapies, aligns with a broader industry trend but requires significant investment and expertise, where larger pharmaceutical companies often have established capabilities.
• The company's R&D spending, while increasing, is typical for a biopharmaceutical company with a diversified pipeline, including multiple Phase 3 and Phase 1 initiations, and investments in gene therapy and preclinical programs.

Management Changes

Corporate Governance

Legal Proceedings

• In March 2025, received a notice from Zydus Lifesciences Global FZE regarding an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of INGREZZA SPRINKLE, alleging patent invalidity/non-infringement.
• Filed suit in April 2025 in the U.S. District Court for the District of Delaware and New Jersey against Zydus Pharmaceuticals (USA) Inc. and affiliates to prevent the sale of generic INGREZZA SPRINKLE.
• In January 2025, filed suit in the U.S. District Court for the District of Delaware against Spruce Biosciences, Inc. seeking a declaratory judgment of invalidity of one of Spruce's patents; case dismissed without prejudice in June 2025.
• Initiated post-grant review against another Spruce patent in the U.S. Patent and Trademark Office in January 2025, leading to Spruce disclaiming all challenged claims.
• Received a civil investigative demand from the U.S. Department of Justice (DOJ) in August 2025 requesting documents and information related to sales and marketing of INGREZZA.
• Received an untitled letter from the FDA Office of Prescription Drug Promotion in September 2025 alleging misleading claims in promotional material for INGREZZA.

Related Party Transactions

• Equity investment in Voyager Therapeutics, Inc. became subject to the equity method of accounting, and Voyager became a related party, following the purchase of 2023 Voyager Shares, resulting in approximately 19.9% ownership of Voyager's voting stock.

Stakeholder Impact

• **Shareholders:** Positive impact from strong revenue growth, increased net income, and ongoing share repurchase programs. Potential negative impact from increased operating expenses, a pipeline setback, and ongoing legal/regulatory risks.
• **Patients:** Positive impact from the launch of CRENESITY for CAH and continued commercialization of INGREZZA for TD and Huntington's disease. Potential for new treatments from advancing pipeline candidates (schizophrenia, MDD, epilepsy, CAH).
• **Employees:** Increased headcount and planned expansion of sales teams indicate growth opportunities. Potential impact from managing rapid growth and transformation into biologics development.
• **Customers (Healthcare Providers & Payors):** Expanded formulary access for INGREZZA improves coverage. New product CRENESITY offers a first-in-class treatment option. Potential impact from drug pricing controls and reimbursement policies.
• **Suppliers & Collaborators:** Continued reliance on third-party suppliers and collaborators for manufacturing and R&D, with potential for future milestone payments. Termination of some collaboration programs with Voyager and Takeda.

Next Steps

• Complete expansion of INGREZZA and CRENESITY sales teams by the end of the first quarter of 2026.
• Continue Phase 3 clinical studies for direclidine in schizophrenia.
• Continue Phase 3 clinical study for osavampator in MDD.
• Continue Phase 1 clinical studies for NBIP-1435 (CAH), NBI-921355 (epilepsy), and NBI-1140675 (neurological/neuropsychiatric conditions).
• Address the civil investigative demand from the U.S. Department of Justice regarding INGREZZA sales and marketing.
• Respond to the FDA Office of Prescription Drug Promotion's untitled letter regarding INGREZZA promotional material.
• Continue to evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Expense Disaggregation Disclosures) on financial statement disclosures.
• Continue share repurchases under the $500.0 million 2025 Repurchase Program, with $332.3 million remaining as of September 30, 2025.

Key Dates

Recommendation

Neurocrine Biosciences demonstrates robust financial health with significant revenue growth driven by its flagship product INGREZZA and the successful launch of CRENESITY. The company's active and diverse pipeline, with multiple candidates advancing into late-stage clinical trials and positive data readouts, signals strong future growth potential. Strategic market access for INGREZZA, including its exemption from Medicare price negotiation until 2029, provides a competitive advantage. While increased operating expenses and a Phase 3 setback for one valbenazine indication are noted, these are outweighed by overall strong performance, effective capital management through share repurchases, and a clear strategic direction. The ongoing legal and regulatory challenges are typical for the pharmaceutical industry and appear manageable based on current disclosures. The company's strong cash position and working capital further support its ability to fund future growth and innovation.

Keywords

Neurocrine Biosciences, NBIX, Pharmaceuticals, Biotechnology, Neuroscience, INGREZZA, Valbenazine, Tardive Dyskinesia, Huntington's Disease, Chorea, CRENESITY, Crinecerfont, Congenital Adrenal Hyperplasia, CAH, Direclidine, Schizophrenia, Osavampator, Major Depressive Disorder, MDD, Pipeline, Clinical Trials, Phase 3, Phase 1, SEC Filing, 10-Q, Financial Results, Revenue Growth, R&D, Share Repurchase, Medicare Drug Price Negotiation, FDA, Biologics, Gene Therapy, Intellectual Property, Cybersecurity, Data Privacy